Pharma Deal Frenzy May Continue in 2016, Jefferies Survey FindsBy
77% of those surveyed see M&A activity levels steady or rising
About 20 percent see overpaying as risk as premiums stay high
The record year for pharmaceutical and biotech deals may spill over into 2016, according to a survey by Jefferies Group LLC.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.